SAN DIEGO and WARSAW, Oct. 24, 2013 – Warsaw-based Mediserv, a distributor of equipment for the treatment of sleep disordered-breathing and respiratory disorders, has been acquired by ResMed (NYSE: RMD), a pioneer and global leader in sleep and respiratory medicine.
“One in four adults stops breathing multiple times throughout the night as a result of mild to severe sleep apnea,” said Tomasz Zarzycki, commercial director for ResMed- Emerging Markets. “Our agreement with Mediserv will allow us to expand our reach to help more of our citizens obtain comfortable and effective treatment for sleep apnea and other respiratory disorders.”
Mediserv will continue to serve its existing patients but, under ResMed’s ownership, will expand its service to include cardiology as well as home care and hospital respiratory care populations. Mediserv is expected to transition to its new name of ResMed-Poland within six months.
“Mediserv has carried ResMed products because we wanted our patients to have the best treatment options for their sleep-disordered breathing (SDB),” said Fayez Afana, owner and general manager of Mediserv. “With this acquisition, ResMed can more rapidly introduce its new technologies for SDB patients as well as those who require ventilation, either at home or in hospital, and ResMed will be closer to the patient to promote awareness of SDB problems in Poland.”
“Having a direct presence in Poland is similar to our model in other European countries, and it will allow us to better serve our home care providers for respiratory care and other sleep and breathing therapy needs,” said ResMed-Europe President, Anne Reiser.
Dr. Eng. Afana will continue to fully support the business in his role as a full-time consultant.
Under ResMed ownership, the Mediserv organization will be strengthened by additional customer service, commercial, technical and clinical resources both in Warsaw as well as across the country.
As a result, ResMed customers and patients will receive enhanced support in these areas. Terms of the deal were not disclosed.